Seegene reveals innovative unattended Polymerase Chain Reaction (PCR) automation, catalyzing a worldwide diagnostic transformation at ADLM 2025 event

Seegene reveals innovative unattended Polymerase Chain Reaction (PCR) automation, catalyzing a worldwide diagnostic transformation at ADLM 2025 event

Seegene Inc., a leading innovator in molecular diagnostics, is set to unveil its groundbreaking CURECATM system at ADLM 2025. This fully automated PCR testing platform promises to revolutionise the diagnostic industry by carrying out the entire diagnostic workflow without human intervention[1][2][4].

CURECATM is designed to handle diverse specimen types such as stool, urine, blood, and sputum, making it an ideal solution for high-throughput and rapid testing environments[1][2][3]. By minimising human error, increasing efficiency, and improving the consistency and reliability of PCR test results, CURECATM is poised to make a significant impact in the diagnostic industry[1][2][3].

Complementing CURECATM is Seegene’s STAgoraTM, a big data analytics platform that unifies global diagnostic data. STAgoraTM aims to transform diagnostics through enhanced data analytics, enabling more informed healthcare decisions and fostering a new global diagnostics paradigm[1][4]. By providing integrated insights into regional infection trends, hospital-level positivity rates, and patterns of co-infection, STAgoraTM offers a powerful tool for epidemiological monitoring and research[1].

CURECATM's prep module is not limited to PCR diagnostics, but is also applicable to pre-treatment for clinical chemistry and immunoassays[2]. The fully automated prep module addresses challenges in pre-treatment, particularly with diverse sample types like stool[2].

Seegene's syndromic real-time PCR technology, including CURECATM and STAgoraTM, was particularly highlighted during the COVID-19 pandemic, with Seegene providing over 340 million COVID-19 tests to more than 100 countries worldwide[1].

As the world grapples with infectious diseases, the synergy of CURECATM and STAgoraTM signals a transformative shift towards fully automated, data-integrated diagnostics at a global level, setting new industry gold standards[1][4]. Seegene aims to broaden access to these technologies by offering early pilot experiences and establishing new global partnerships.

For more information about Seegene's CURECATM and STAgoraTM, visit Seegene.com and follow linkedin.com/company/seegene-inc for updates.

[1] Seegene Inc. Press Release, 'Seegene to Showcase CURECATM, the World's First Fully Automated PCR Testing System at ADLM 2025', 2025. [2] Seegene Inc. Technical Specifications, 'CURECATM Prep Module', 2025. [3] Seegene Inc. Whitepaper, 'The Impact of CURECATM on Molecular Diagnostics', 2025. [4] Seegene Inc. Brochure, 'STAgoraTM: Transforming Diagnostics through Enhanced Data Analytics', 2023.

The innovative CURECATM system, set to debut at ADLM 2025, will leverage technology to revolutionize medical-conditions diagnosis and health-and-wellness by automating the entire diagnostic workflow, including diverse specimen types like stool, urine, blood, and sputum. Seegene's STAgoraTM, a big data analytics platform, will work in conjunction with CURECATM to transform the diagnostic industry through enhanced data analytics, leading to science-based healthcare decisions and setting new industry standards.

Read also: